Eupatilin inhibits angiogenesis-mediated human hepatocellular metastasis by reducing MMP-2 and VEGF signaling

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metastasis is a primary cause of cancer-related mortality.
• Matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, are crucial for tumor cell migration and invasion.
• Identifying novel therapeutic agents to inhibit metastasis is a critical unmet need in cancer treatment.

Purpose of the Study:

• To investigate the inhibitory effects of eupatilin on matrix metalloproteinase (MMP) expression in SNU182 cells.
• To evaluate the anti-angiogenic potential of eupatilin on human umbilical vein vascular endothelial cells (HUVECs).
• To explore the molecular mechanisms underlying eupatilin's anti-metastatic effects.

Main Methods:

• Quantitative real-time PCR was used to measure MMP-2 and MMP-9 mRNA levels.
• Tube formation assays were performed on HUVECs treated with eupatilin.
• Expression levels of hypoxia-inducible factor 1-alpha (HIF-1α), vascular endothelial growth factor (VEGF), and phosphorylated Akt were analyzed.

Main Results:

• Eupatilin significantly suppressed MMP-2 mRNA transcription in SNU182 cells.
• Eupatilin inhibited tube formation in HUVECs at concentrations of 3.125 and 6.25 μg/mL.
• Eupatilin demonstrated anti-angiogenic potential by down-regulating HIF-1α, VEGF, and phosphorylated Akt expression.

Conclusions:

• Eupatilin exhibits anti-metastatic properties by inhibiting MMP-2-mediated migration.
• Eupatilin possesses significant anti-angiogenic activity, suggesting its potential as a therapeutic agent for hepatocellular carcinoma.
• Targeting tube formation and MMP-2-dependent migration are key mechanisms for eupatilin's efficacy in combating cancer metastasis.